NCT04953715View on ClinicalTrials.gov

Microbiome and Immunosuppression: The Mission Study

Active, not recruitingOBSERVATIONAL
Enrollment

140

Participants

Timeline

Start Date

February 12, 2020

Primary Completion Date

January 1, 2032

Study Completion Date

January 1, 2033

Conditions
Kidney Transplant RejectionKidney Transplant
Interventions
OTHER

collection of body microbiome

A prospective, observational microbiome study of adult kidney transplant recipients receiving mycophenolate mofetil and tacrolimus maintenance immunosuppression. Participants will be studied post-transplant for mycophenolate pharmacokinetics and microbiome samples collected. Clinically measured tacrolimus trough concentrations will also be evaluated. Associations among mycophenolic acid enterohepatic recycling and metabolite formation, tacrolimus troughs, immunosuppression adverse effects, diarrhea and microbiome will be studied.

Trial Locations (2)

55414

University of Minnesota, Minneapolis

55415

HCMC, Minneapolis

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

The University of Texas Medical Branch, Galveston

OTHER